MCID: RBL001
MIFTS: 62

Rubella

Categories: Eye diseases, Fetal diseases, Infectious diseases, Liver diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 44 Rubella is an infection caused by a virus. It is usually mild with fever and a rash. About half of the people who get rubella do not have symptoms. If you do get them, symptoms may include A rash that starts on the face and spreads to the body Mild fever Aching joints, especially in young women Swollen glands Rubella is most dangerous for a pregnant woman's baby. It can cause miscarriage or birth defects. Rubella spreads when an infected person coughs or sneezes. People without symptoms can still spread it. There is no treatment, but the measles-mumps-rubella (MMR) vaccine can prevent it. Centers for Disease Control and Prevention

MalaCards based summary : Rubella, also known as german measles, is related to acute disseminated encephalomyelitis and mumps, and has symptoms including fever, headache and conjunctivitis. An important gene associated with Rubella is MOG (Myelin Oligodendrocyte Glycoprotein), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and eye.

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Rubella virus, which is transmitted by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 77 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 407, show less)
# Related Disease Score Top Affiliating Genes
1 acute disseminated encephalomyelitis 32.2 HLA-B HLA-DQB1 HLA-DRB1 IL10 MOG
2 mumps 32.0 HLA-DPB1 HLA-DRB1 IFNAR2 IL10RB TNF
3 tetanus 30.7 CD40LG IL10 IL4
4 pertussis 30.6 CALM1 IL10 TNF
5 myelitis 30.6 HLA-DPB1 MOG TNF
6 arthritis 30.6 HLA-DQB1 HLA-DRB1 IL10 TNF
7 optic neuritis 30.6 HLA-DRB1 MOG TNF
8 juvenile rheumatoid arthritis 30.5 HLA-DPB1 HLA-DRB1 TNF
9 poliomyelitis 30.5 IL10 IL4 TNF
10 neuritis 30.4 IL4 MOG TNF
11 cytomegalovirus infection 30.3 HLA-A HLA-B TNF
12 pneumonia 30.2 CD40LG IL10 TNF
13 uveitis 30.2 HLA-B IL10 IL4 TNF
14 toxoplasmosis 30.1 CD40LG HLA-DQB1 IL10 IL4 TNF
15 lupus erythematosus 30.0 CALR CD40LG IL10 TNF
16 herpes zoster 30.0 HLA-A HLA-B IL10
17 rheumatic fever 29.9 HLA-DRB1 IL10 TNF
18 chlamydia 29.9 IL10 IL4 TNF
19 diabetes mellitus 29.9 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
20 recurrent respiratory papillomatosis 29.8 HLA-DQB1 HLA-DRB1
21 rheumatoid arthritis 29.8 CD40LG HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
22 multiple sclerosis 29.8 HLA-DQB1 HLA-DRB1 IL10 IL4 MOG TNF
23 human immunodeficiency virus infectious disease 29.7 IL10 TNF TRIM5
24 intermediate uveitis 29.7 HLA-B IL10 TNF
25 complex regional pain syndrome 29.7 HLA-B IL10 TNF
26 myocarditis 29.6 CD40LG HLA-B HLA-DQB1 TNF
27 vasculitis 29.6 CD40LG HLA-B TNF
28 acquired immunodeficiency syndrome 29.6 HLA-B IL10 TNF
29 inflammatory bowel disease 29.5 IL10 IL10RB IL4 TNF
30 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.5 CD40LG IL10 IL4 TRIM5
31 hematopoietic stem cell transplantation 29.4 HLA-A HLA-B IL10 TNF
32 rheumatic disease 29.3 CD40LG HLA-B HLA-DRB1 IL10 TNF
33 asthma 29.3 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL4
34 human immunodeficiency virus type 1 29.2 HLA-A HLA-B IL10 TNF TRIM5
35 panuveitis 29.1 HLA-A HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
36 diabetes mellitus, insulin-dependent 29.1 HLA-A HLA-DQB1 HLA-DRB1 IL10 IL4
37 aplastic anemia 29.0 HLA-A HLA-B HLA-DRB1 IL4 TNF
38 autoimmune disease 29.0 CD40LG HLA-DQB1 HLA-DRB1 IL10 IL4 MOG
39 colitis 28.9 IL10 IL10RB IL4 TNF
40 systemic lupus erythematosus 28.9 CALR CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
41 malaria 28.7 CD40LG HLA-A HLA-B HLA-DRB1 IL10 IL4
42 congenital rubella 12.9
43 rubella panencephalitis 12.2
44 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 12.1
45 measles 11.8
46 congenital toxoplasmosis 11.3
47 gianotti crosti syndrome 11.3
48 microcephaly 11.2
49 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0
50 immunodeficiency 45 11.0
51 congenital intrauterine infection-like syndrome 11.0
52 togaviridae disease 11.0
53 torch syndrome 11.0
54 immune-mediated encephalomyelitis 11.0
55 postinfectious encephalomyelitis 11.0
56 chickenpox 10.7
57 autism 10.5
58 hepatitis 10.5
59 berylliosis 10.5 HLA-DPB1 HLA-DRB1
60 limbic encephalitis with lgi1 antibodies 10.4 HLA-DQB1 HLA-DRB1
61 encephalitis 10.4
62 necatoriasis 10.4 CALR IL10
63 cataract 10.4
64 narcolepsy 2 10.4 HLA-DQB1 HLA-DRB1
65 autoimmune polyglandular syndrome type 3 10.4 HLA-DQB1 HLA-DRB1
66 hepatitis b 10.4
67 diphtheria 10.4
68 cow milk allergy 10.4 IL10 TNF
69 hypersomnia 10.3 HLA-DQB1 HLA-DRB1
70 phenytoin or carbamazepine toxicity 10.3 HLA-A HLA-B
71 transient hypogammaglobulinemia 10.3 IL10 TNF
72 narcolepsy 1 10.3 HLA-DQB1 HLA-DRB1 MOG
73 juvenile myasthenia gravis 10.3 HLA-DRB1 IL10
74 pediatric multiple sclerosis 10.3 HLA-DQB1 HLA-DRB1 MOG
75 scleritis 10.3 IL4 TNF
76 punctate inner choroidopathy 10.3 IL10 TNF
77 purpura 10.3
78 meningitis 10.3
79 retinitis pigmentosa 22 10.3 IL10 IL4
80 nickel allergic contact dermatitis 10.3 IL10 IL4
81 baylisascariasis 10.3 IL10 IL4
82 neuromyelitis optica 10.3 HLA-DPB1 HLA-DRB1 MOG
83 metal allergy 10.3 HLA-DQB1 HLA-DRB1
84 drug reaction with eosinophilia and systemic symptoms 10.3 HLA-B TNF
85 lichen planopilaris 10.3 HLA-DQB1 HLA-DRB1
86 microscopic colitis 10.2 HLA-DQB1 HLA-DRB1 TNF
87 type ii mixed cryoglobulinemia 10.2 HLA-DQB1 HLA-DRB1
88 sporotrichosis 10.2 CALM1 CD40LG IL10
89 herpes simplex 10.2
90 haemophilus influenzae 10.2
91 atrial tachyarrhythmia with short pr interval 10.2 HLA-A HLA-B
92 htlv-1 associated myelopathy/tropical spastic paraparesis 10.2 HLA-A HLA-B
93 microscopic polyangiitis 10.2 HLA-DRB1 TNF
94 peanut allergy 10.2 HLA-DQB1 HLA-DRB1 IL10
95 aseptic meningitis 10.2
96 pure red-cell aplasia 10.2 HLA-A HLA-DQB1 HLA-DRB1
97 idiopathic achalasia 10.2 HLA-DQB1 IL10 TNF
98 hemorrhagic fever with renal syndrome 10.2 HLA-B HLA-DRB1 TNF
99 postherpetic neuralgia 10.2 HLA-A HLA-B HLA-DRB1
100 pars planitis 10.2 HLA-A HLA-B HLA-DRB1
101 ocular cicatricial pemphigoid 10.2 HLA-DQB1 HLA-DRB1 IL4
102 idiopathic inflammatory myopathy 10.2 HLA-B HLA-DRB1
103 histoplasmosis 10.2 HLA-A HLA-B HLA-DRB1
104 multifocal choroiditis 10.2 IL10 TNF
105 mixed connective tissue disease 10.2 HLA-DRB1 IL10 TNF
106 sclerosing cholangitis 10.2 HLA-B HLA-DRB1 TNF
107 choroiditis 10.2 IL10 TNF
108 leukemia 10.2
109 syphilis 10.2
110 influenza 10.2
111 cholangitis 10.2 HLA-B HLA-DRB1 TNF
112 hyperlucent lung 10.1 IL10 IL4
113 dengue shock syndrome 10.1 HLA-A HLA-DRB1 TNF
114 palindromic rheumatism 10.1 HLA-A HLA-DRB1 TNF
115 celiac disease 1 10.1 CALR HLA-A HLA-DQB1
116 buruli ulcer 10.1 CD40LG IL10 IL4
117 transient hypogammaglobulinemia of infancy 10.1 CD40LG IL10 IL4
118 narcolepsy 10.1 HLA-DQB1 HLA-DRB1 MOG TNF
119 joint disorders 10.1
120 lymphocytic leukemia 10.1
121 arthropathy 10.1
122 uveal disease 10.1 HLA-B IL10 TNF
123 reactive arthritis 10.1 HLA-B IL10 TNF
124 autoimmune hepatitis 10.1 HLA-A HLA-DQB1 HLA-DRB1
125 beryllium disease 10.1 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
126 chronic beryllium disease 10.1 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
127 retinitis pigmentosa 75 10.1 IL10RB TNF
128 oligoarticular juvenile idiopathic arthritis 10.1 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
129 mycobacterium tuberculosis 1 10.1 IL10 IL4 TNF
130 leukemia, acute lymphoblastic 10.1
131 hepatitis a 10.1
132 anterior uveitis 10.1
133 severe cutaneous adverse reaction 10.1 HLA-A HLA-B TNF
134 tropical endomyocardial fibrosis 10.1 IL10 IL4 TNF
135 endomyocardial fibrosis 10.1 IL10 IL4 TNF
136 chagas disease 10.1 CALR IL10 TNF
137 demyelinating disease 10.1 CD40LG IL10 MOG TNF
138 tungiasis 10.1 IL10 IL4 TNF
139 immune deficiency disease 10.1 CD40LG IL10 IL4
140 autoimmune gastritis 10.1 IL10 IL4 TNF
141 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.1
142 thrombocytopenia 10.1
143 japanese encephalitis 10.1
144 guillain-barre syndrome 10.1
145 orofacial granulomatosis 10.1 IL10 IL4 TNF
146 mycoplasma pneumoniae pneumonia 10.1 IL10 IL4 TNF
147 eales disease 10.1 IL10 IL4 TNF
148 coccidiosis 10.1 IL10 IL4 TNF
149 primary progressive multiple sclerosis 10.1 HLA-DRB1 IL10 MOG TNF
150 q fever 10.1 IL10 IL4 TNF
151 acute graft versus host disease 10.1 IL10 IL4 TNF
152 keratoconjunctivitis sicca 10.1 IL10 IL4 TNF
153 extrinsic cardiomyopathy 10.1 IL10 IL4 TNF
154 autoimmune uveitis 10.1 IL10 IL4 TNF
155 idiopathic neutropenia 10.1 CD40LG HLA-DRB1 IL10 TNF
156 paracoccidioidomycosis 10.1 IL10 IL4 TNF
157 opportunistic mycosis 10.1 IL10 IL4 TNF
158 nose disease 10.0 IL10 IL4 TNF
159 parasitic helminthiasis infectious disease 10.0 IL10 IL4 TNF
160 pityriasis rosea 10.0 HLA-A HLA-B HLA-DQB1 HLA-DRB1
161 hemolytic anemia 10.0
162 exanthem 10.0
163 febrile seizures 10.0
164 idiopathic bronchiectasis 10.0 HLA-A HLA-B HLA-DQB1 HLA-DRB1
165 parasitic protozoa infectious disease 10.0 IL10 IL4 TNF
166 bare lymphocyte syndrome, type ii 10.0 HLA-A HLA-DQB1 TRIM22
167 allergic contact dermatitis 10.0 IL10 IL4 TNF
168 inflammatory bowel disease 25 10.0 IL10RB TNF
169 paraneoplastic pemphigus 10.0 HLA-A HLA-B HLA-DQB1 HLA-DRB1
170 contact dermatitis 10.0 IL10 IL4 TNF
171 aggressive periodontitis 10.0 IL10 IL4 TNF
172 periodontitis 10.0 IL10 IL4 TNF
173 myasthenia gravis 10.0 IL10 IL4 TNF
174 upper respiratory tract disease 10.0 IL10 IL4 TNF
175 primary bacterial infectious disease 10.0 IL10 IL4 TNF
176 cutaneous leishmaniasis 10.0 IL10 IL4 TNF
177 gastroenteritis 10.0 IL10 IL4 TNF
178 bronchial disease 10.0 IL10 IL4 TNF
179 visceral leishmaniasis 10.0 IL10 IL4 TNF
180 aspergillosis 10.0 IL10 IL4 TNF
181 echinococcosis 10.0 HLA-B HLA-DRB1 IL10 TNF
182 toxic shock syndrome 10.0 IL10 IL4 TNF
183 cytomegalovirus retinitis 10.0 HLA-A HLA-B HLA-DQB1 TNF
184 thrombocytopenic purpura, autoimmune 10.0
185 panencephalitis, subacute sclerosing 10.0
186 liver disease 10.0
187 autism spectrum disorder 10.0
188 thyroiditis 10.0
189 scarlet fever 10.0
190 fuchs' heterochromic uveitis 10.0
191 bronchiolitis 10.0 IL10 IL4 TNF
192 otitis media 10.0 IL10 IL4 TNF
193 nontuberculous mycobacterial lung disease 10.0 HLA-A HLA-B HLA-DRB1 TNF
194 alveolar echinococcosis 10.0 HLA-A HLA-B HLA-DRB1 TNF
195 proteasome-associated autoinflammatory syndrome 1 10.0 IL10 IL4 TNF
196 relapsing-remitting multiple sclerosis 10.0 IL10 IL4 MOG TNF
197 brucellosis 10.0 CD40LG IL10 IL4 TNF
198 autoimmune disease of musculoskeletal system 10.0 CD40LG IL10 IL4 TNF
199 meningoencephalitis 10.0
200 egg allergy 10.0
201 iridocyclitis 10.0
202 transverse myelitis 10.0
203 schistosomiasis 9.9 CD40LG IL10 IL4 TNF
204 omenn syndrome 9.9 IL10 IL4 TNF
205 trypanosomiasis 9.9 CALR IL10 IL4 TNF
206 inflammatory bowel disease 25, autosomal recessive 9.9 IL10 IL10RB
207 viral infectious disease 9.9 CD40LG IL10 IL4 TNF
208 bone inflammation disease 9.9 HLA-DRB1 IL10 IL4 TNF
209 primary systemic mycosis 9.9 CALM1 IL10 IL4 TNF
210 pulmonary tuberculosis 9.9 HLA-DRB1 IL10 IL4 TNF
211 common variable immunodeficiency 9.9 CD40LG IL10 IL4 TNF
212 connective tissue disease 9.9 CD40LG HLA-DPB1 HLA-DRB1 IL10 TNF
213 behcet syndrome 9.9 HLA-A HLA-B IL10 TNF
214 pfeiffer syndrome 9.9
215 acute liver failure 9.9
216 acute lymphocytic leukemia 9.9
217 hypothyroidism 9.9
218 synovitis 9.9
219 newcastle disease 9.9
220 vaccinia 9.9
221 pancreatitis 9.9
222 infertility 9.9
223 encephalopathy 9.9
224 respiratory system disease 9.9 IL10 IL4 TNF
225 geographic tongue 9.8 HLA-A HLA-B HLA-DQB1 HLA-DRB1 TNF
226 takayasu arteritis 9.8 HLA-A HLA-B HLA-DPB1 HLA-DRB1 TNF
227 immune system disease 9.8 CALR IL10 IL4 MOG TNF
228 vogt-koyanagi-harada disease 9.8 HLA-A HLA-B HLA-DQB1 HLA-DRB1 IL10
229 skin disease 9.8 HLA-B IL10 IL4 TNF
230 autoimmune disease of central nervous system 9.8 HLA-DRB1 IL10 IL4 MOG TNF
231 interstitial lung disease 9.8 IL10 IL4 TNF
232 blood group, colton system 9.8
233 legg-calve-perthes disease 9.8
234 retinoblastoma 9.8
235 strabismus 9.8
236 supravalvular aortic stenosis 9.8
237 digeorge syndrome 9.8
238 anemia, autoimmune hemolytic 9.8
239 australia antigen 9.8
240 rheumatic fever-related antigen 9.8
241 wilms tumor 5 9.8
242 light fixation seizure syndrome 9.8
243 infantile liver failure syndrome 1 9.8
244 wilms tumor 6 9.8
245 pulmonary hypertension 9.8
246 keratoconus 9.8
247 erythema multiforme 9.8
248 sensorineural hearing loss 9.8
249 parotitis 9.8
250 pre-eclampsia 9.8
251 rabies 9.8
252 heart disease 9.8
253 bell's palsy 9.8
254 adult-onset still's disease 9.8
255 status epilepticus 9.8
256 agammaglobulinemia 9.8
257 papilloma 9.8
258 histiocytosis 9.8
259 mutism 9.8
260 hydranencephaly 9.8
261 retinal disease 9.8
262 conjunctivitis 9.8
263 neuropathy 9.8
264 mechanical strabismus 9.8
265 yellow fever 9.8
266 pityriasis lichenoides 9.8
267 myoclonus 9.8
268 atrial standstill 1 9.8
269 leishmaniasis 9.8 HLA-DQB1 HLA-DRB1 IL10 IL4 TNF
270 dengue hemorrhagic fever 9.8 HLA-A HLA-B HLA-DRB1 IL10 TNF
271 rheumatic heart disease 9.7 HLA-B HLA-DRB1 IL10 IL4 TNF
272 glaucomatocyclitic crisis 9.7 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
273 aphthous stomatitis 9.7 HLA-A HLA-B IL10 IL4 TNF
274 spondyloarthropathy 9.7 HLA-A HLA-B IL10 IL4 TNF
275 aniridia 1 9.7
276 leukemia, chronic lymphocytic 2 9.7
277 deafness, unilateral 9.7
278 hashimoto thyroiditis 9.7
279 leukemia, chronic lymphocytic 9.7
280 gnathodiaphyseal dysplasia 9.7
281 pelger-huet anomaly 9.7
282 schizophrenia 9.7
283 neural tube defects 9.7
284 wolff-parkinson-white syndrome 9.7
285 hypothyroidism, congenital, nongoitrous, 2 9.7
286 diastrophic dysplasia 9.7
287 duodenal atresia 9.7
288 galactosemia 9.7
289 jejunal atresia 9.7
290 myeloma, multiple 9.7
291 myxedema 9.7
292 interstitial pneumonitis, desquamative, familial 9.7
293 retinitis pigmentosa 9.7
294 graves disease 1 9.7
295 pigmentary disorder, reticulate, with systemic manifestations, x-linked 9.7
296 choroideremia 9.7
297 immunodeficiency with hyper-igm, type 1 9.7
298 yemenite deaf-blind hypopigmentation syndrome 9.7
299 dermatitis, atopic 9.7
300 leber congenital amaurosis 4 9.7
301 patent ductus arteriosus 1 9.7
302 autoimmune disease 1 9.7
303 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
304 noonan syndrome 4 9.7
305 kawasaki disease 9.7
306 muscle hypertrophy 9.7
307 dengue virus 9.7
308 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.7
309 deficiency anemia 9.7
310 acute leukemia 9.7
311 acute lymphoblastic leukemia, childhood 9.7
312 adult respiratory distress syndrome 9.7
313 chronic granulomatous disease 9.7
314 dengue disease 9.7
315 hydrocephalus 9.7
316 keratopathy 9.7
317 severe combined immunodeficiency 9.7
318 systemic scleroderma 9.7
319 chikungunya 9.7
320 desquamative interstitial pneumonia 9.7
321 tick-borne encephalitis 9.7
322 congenital hypothyroidism 9.7
323 exanthema subitum 9.7
324 variola major 9.7
325 cd40 ligand deficiency 9.7
326 inguinal hernia 9.7
327 salmonellosis 9.7
328 thrombosis 9.7
329 immunodeficiency-centromeric instability-facial anomalies syndrome 9.7
330 bacterial infectious disease 9.7
331 protein-losing enteropathy 9.7
332 microphthalmia 9.7
333 partial third-nerve palsy 9.7
334 abducens nerve disease 9.7
335 hemiplegia 9.7
336 corneal edema 9.7
337 prostatic hypertrophy 9.7
338 anogenital venereal wart 9.7
339 pneumocystosis 9.7
340 congenital aphakia 9.7
341 autonomic neuropathy 9.7
342 retinal vasculitis 9.7
343 onchocerciasis 9.7
344 dysgammaglobulinemia 9.7
345 iron deficiency anemia 9.7
346 esophagitis 9.7
347 typhoid fever 9.7
348 bejel 9.7
349 eclampsia 9.7
350 biliary atresia 9.7
351 hepatitis c 9.7
352 encephalomalacia 9.7
353 enthesopathy 9.7
354 transient arthritis 9.7
355 iron metabolism disease 9.7
356 orchitis 9.7
357 dermatitis 9.7
358 bilirubin metabolic disorder 9.7
359 food allergy 9.7
360 carotid artery thrombosis 9.7
361 plague 9.7
362 retinitis 9.7
363 acute myocarditis 9.7
364 aortic valve insufficiency 9.7
365 peripheral nervous system disease 9.7
366 lymphopenia 9.7
367 combined t cell and b cell immunodeficiency 9.7
368 viral esophagitis 9.7
369 progressive multifocal leukoencephalopathy 9.7
370 hyperthyroidism 9.7
371 peritonitis 9.7
372 appendicitis 9.7
373 bullous pemphigoid 9.7
374 malignant histiocytosis 9.7
375 smallpox 9.7
376 erythema infectiosum 9.7
377 molluscum contagiosum 9.7
378 lichen planus 9.7
379 cleft lip 9.7
380 stomatitis 9.7
381 irritable bowel syndrome 9.7
382 hemophilia 9.7
383 allergic encephalomyelitis 9.7
384 central serous chorioretinopathy 9.7
385 congenital cytomegalovirus 9.7
386 cytomegalic inclusion disease 9.7
387 desmoplastic infantile astrocytoma 9.7
388 dwarfism 9.7
389 encephalocele 9.7
390 growth hormone deficiency 9.7
391 leukemia, b-cell, chronic 9.7
392 lymphocytic hypophysitis 9.7
393 parvovirus antenatal infection 9.7
394 pityriasis lichenoides et varioliformis acuta 9.7
395 polymorphic reticulosis 9.7
396 polymyositis 9.7
397 rosai-dorfman disease 9.7
398 tracheoesophageal fistula 9.7
399 treponema infection 9.7
400 virus associated hemophagocytic syndrome 9.7
401 xp22.3 microdeletion syndrome 9.7
402 depression 9.7
403 cleft lip/palate 9.7
404 hemophagocytic syndrome associated with an infection 9.7
405 occipital encephalocele 9.7
406 graft-versus-host disease 9.5 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
407 dilated cardiomyopathy 9.4 CALR HLA-DQB1 HLA-DRB1 IL10 TNF

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

Symptoms:

12 (showing 6, show less)
  • fever
  • headache
  • conjunctivitis
  • lymphadenopathy
  • joint pains
  • rash on the face which spreads to the trunk

UMLS symptoms related to Rubella:


fever, pruritus, exanthema

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 83, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
2 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
3 Liver Extracts Phase 4
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
7 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
8
Tetracycline Approved, Vet_approved Phase 3,Phase 1,Phase 2 60-54-8 5353990
9
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
10
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
11
Petrolatum Approved, Investigational Phase 3 8009-03-8
12
Podophyllin Approved Phase 3 9000-55-9
13
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
14
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
15
Lactitol Investigational Phase 3,Phase 2 585-88-6, 585-86-4 493591
16
Cobalamin Experimental Phase 3 13408-78-1 6857388
17 Hemagglutinins Phase 3
18 Somatomedin B Phase 3
19 taxane Phase 3
20 Anti-Infective Agents Phase 3,Phase 1,Phase 2
21 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
22 Vitamin B12 Phase 3
23 Vitamin B 12 Phase 3
24 PENTA Phase 3,Phase 2
25 Vitamins Phase 3
26 Antioxidants Phase 3
27 Trace Elements Phase 3
28 Micronutrients Phase 3
29 Protective Agents Phase 3,Phase 2
30 Nutrients Phase 3
31 Retinol palmitate Phase 3
32 retinol Phase 3
33 insulin Phase 3
34 Insulin, Globin Zinc Phase 3
35 Dermatologic Agents Phase 3
36 Keratolytic Agents Phase 3
37 Antineoplastic Agents, Phytogenic Phase 3
38
Altretamine Approved Phase 2 645-05-6 2123
39
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
40
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
41
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
42
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
43
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
44
Mycophenolic acid Approved Phase 2 24280-93-1 446541
45
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
46
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
47
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
48 Anticoagulants Phase 2
49 Fibrinolytic Agents Phase 2
50 Antineoplastic Agents, Immunological Phase 2,Phase 1
51 Proteasome Inhibitors Phase 2
52 Prednisolone acetate Phase 2
53 glucocorticoids Phase 2
54 Peripheral Nervous System Agents Phase 2
55 Neuroprotective Agents Phase 2
56 Anti-Inflammatory Agents Phase 2
57 Antitubercular Agents Phase 2
58 Antiemetics Phase 2
59 Antibiotics, Antitubercular Phase 2
60 Antineoplastic Agents, Hormonal Phase 2
61 Methylprednisolone Acetate Phase 2
62 Gastrointestinal Agents Phase 2
63 Hormones Phase 2
64 Autonomic Agents Phase 2
65 Hormone Antagonists Phase 2
66 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
67 Immunoglobulin G Phase 1
68 Immunoglobulin M Phase 1
69 Autoantibodies Phase 1
70 Rho(D) Immune Globulin Phase 1
71 Immunoglobulins, Intravenous Phase 1
72 gamma-Globulins Phase 1
73
Adenosine Approved, Investigational 58-61-7 60961
74
Certolizumab pegol Approved 428863-50-7
75
Azathioprine Approved 446-86-6 2265
76
Infliximab Approved 170277-31-3
77
Adalimumab Approved 331731-18-1 16219006
78
Mercaptopurine Approved 50-44-2 667490
79
Methotrexate Approved 1959-05-2, 59-05-2 126941
80 Acidophilus Not Applicable
81 Adjuvants, Immunologic
82 Anti-Retroviral Agents Not Applicable
83 Anti-HIV Agents Not Applicable

Interventional clinical trials:

(showing 166, show less)
# Name Status NCT ID Phase Drugs
1 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Unknown status NCT03071575 Phase 4
2 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
3 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Unknown status NCT01770119 Phase 4
4 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
5 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
6 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
7 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
8 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
9 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
10 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
11 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
12 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Completed NCT03368495 Phase 4
13 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
14 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
15 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
16 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
17 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
18 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
19 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
20 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
21 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
22 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
23 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
24 MMR at 6 Months Trial Recruiting NCT03780179 Phase 4
25 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
26 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
27 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
28 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
29 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
30 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
31 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
32 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
33 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
34 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
35 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
36 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
37 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
38 Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III) Completed NCT03713359 Phase 3
39 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
40 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
41 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
42 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
43 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed NCT00432042 Phase 3
44 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
45 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
46 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
47 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
48 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
49 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
50 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
51 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
52 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
53 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
54 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3
55 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
56 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed NCT00566527 Phase 3
57 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) Completed NCT00109343 Phase 3
58 Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes Completed NCT00351923 Phase 3
59 Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years Completed NCT00871117 Phase 3
60 A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) Completed NCT00092391 Phase 3
61 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines Completed NCT00984295 Phase 3
62 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
63 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers Completed NCT00626327 Phase 3
64 Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route Completed NCT00432523 Phase 3
65 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed NCT00384397 Phase 3
66 Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 Completed NCT00263653 Phase 3
67 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
68 Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children Completed NCT00474266 Phase 3
69 Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines Completed NCT01307436 Phase 3
70 Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) Completed NCT02062502 Phase 3
71 Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed) Completed NCT00822237 Phase 3
72 Evaluation of Immunogenicity and Safety of VARIVAX™ Passage Extension 34 (PE34) Process in Children (V210-A03) Completed NCT03239873 Phase 3
73 Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age Completed NCT01346293 Phase 3
74 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers Completed NCT00847145 Phase 3
75 Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) Completed NCT01553279 Phase 3
76 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine Completed NCT00289783 Phase 3
77 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. Completed NCT00345683 Phase 3
78 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months Completed NCT01000311 Phase 3
79 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) Completed NCT01341639 Phase 3
80 Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. Completed NCT00871000 Phase 3
81 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers Completed NCT03205371 Phase 3
82 Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children Completed NCT01245049 Phase 3
83 Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00806195 Phase 3
84 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Completed NCT01139021 Phase 3
85 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
86 Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine Completed NCT00373958 Phase 3
87 Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old Completed NCT01627561 Phase 3
88 Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination Completed NCT01839175 Phase 3
89 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants Completed NCT00474526 Phase 3
90 Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Recruiting NCT03148990 Phase 2, Phase 3
91 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe Recruiting NCT03547271 Phase 3
92 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US Recruiting NCT03537508 Phase 3
93 Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Philippines, the Russian Federation, and Mexico Recruiting NCT03630705 Phase 3
94 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers Recruiting NCT03673462 Phase 3
95 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers Recruiting NCT03691610 Phase 3
96 GlaxoSmithKline's (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants Recruiting NCT03621670 Phase 3
97 A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Recruiting NCT03620162 Phase 3
98 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
99 Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants Active, not recruiting NCT03197376 Phase 3
100 Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts Not yet recruiting NCT03853785 Phase 3 Topical Podophyllin
101 Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) Not yet recruiting NCT03893448 Phase 3
102 Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Not yet recruiting NCT03933098 Phase 3
103 A Study of ProQuad™ in Healthy Children in Korea (V221-023) Terminated NCT00839917 Phase 3
104 A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062) Withdrawn NCT01626794 Phase 3
105 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Completed NCT00892775 Phase 1, Phase 2
106 Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age Completed NCT00861744 Phase 2
107 Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) Completed NCT00092404 Phase 2
108 Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ Completed NCT00353288 Phase 2
109 Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ Completed NCT00352898 Phase 2
110 Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months Completed NCT00192166 Phase 2
111 A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Completed NCT00109278 Phase 2
112 ProQuad Dose Selection Study (V221-011)(COMPLETED) Completed NCT00986232 Phase 2
113 Zambia SiVET MMR Tdap-IPV Completed NCT02589678 Phase 1, Phase 2
114 Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Completed NCT00578175 Phase 2
115 Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines Completed NCT00134719 Phase 2
116 A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group Completed NCT00000815 Phase 2
117 Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine Completed NCT02861586 Phase 2
118 B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants Completed NCT00488683 Phase 2
119 Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study Completed NCT00381615 Phase 2
120 Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) Completed NCT00310856 Phase 2
121 Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants Completed NCT00262002 Phase 2
122 Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). Completed NCT00792623 Phase 2
123 Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Recruiting NCT02102594 Phase 2 Bortezomib
124 Baby Vaccine Study (Sched3) Active, not recruiting NCT02482636 Phase 2
125 Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area Active, not recruiting NCT03101111 Phase 2
126 Prospective Trial of Vaccine Responses in Childhood Cancer Survivors Active, not recruiting NCT00505063 Phase 2
127 A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) Active, not recruiting NCT02550652 Phase 2 Mycophenolate Mofetil/Mycophenolic Acid;Obinutuzumab;Methylprednisolone;Prednisone
128 Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Active, not recruiting NCT03527355 Phase 2
129 Immune Responses to Two Dose Varivax +/- MMR-II Terminated NCT00258726 Phase 1, Phase 2
130 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
131 Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Completed NCT02196285 Phase 1
132 A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation Completed NCT02586051 Phase 1 Obinutuzumab;Intravenous Immunoglobulin
133 The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants Unknown status NCT00645996 Not Applicable
134 MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component. Unknown status NCT02712203
135 Ontogeny of Measles Immunity in Infants Unknown status NCT00240916
136 Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease Unknown status NCT00932269
137 Bioarray for the Serological Assessment of Immunity Against Vaccine-preventable Infections Unknown status NCT03107312
138 Susceptibility Genes in Autism Spectrum Disorders Unknown status NCT02628808
139 300 Antibody Diagnostic Test Kit Unknown status NCT01646411
140 Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination Completed NCT02158364 Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
141 Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination Completed NCT02151773 Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
142 Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies Completed NCT02934295 Not Applicable
143 Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) Completed NCT01874457
144 Rubella Susceptibility in Multiparous Women Completed NCT00401505
145 Measles, Mumps, and Rubella (MMR) Immunity in College Students Completed NCT00962819
146 Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant Completed NCT02687763 Early Phase 1
147 Making Decisions About the Measles-Mumps-Rubella Vaccine Completed NCT01369394 Not Applicable
148 MMR and Varicella Vaccine in Premature Infants Completed NCT00156559
149 Altruistically Framed Messages and Impact on Parents' Reported Willingness to Immunize Their Children Completed NCT02015689 Not Applicable
150 Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients Completed NCT02434133
151 Blood-borne Infection Screening in an Afghan Antenatal Population Completed NCT01199601 Not Applicable
152 Iridocorneal Angle and Anterior Segment Structure in Eyes of Children With Cataract Completed NCT03778086
153 Duration of Long-term Immunity After Hepatitis B Virus Immunization Completed NCT01182311
154 Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs Completed NCT00013871 Not Applicable
155 Seroepidemiological Study of Pertussis and Other Infectious Diseases Completed NCT01929473
156 Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs Completed NCT00257127 Not Applicable
157 Expanded Noninvasive Genomic Medical Assessment: The Enigma Study Completed NCT02787486
158 Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan) Completed NCT01521897
159 Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina Completed NCT01544764 Not Applicable
160 Vaccination Coverage and Level of Protection in Patients at Risk Recruiting NCT03820752
161 Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children Recruiting NCT03180359 Not Applicable
162 Effectiveness of Educational Program on Parenting Stress and Coping Mechanism Among Parents of Children With Autism Spectrum Disorder in Amman, Jordan Recruiting NCT03805828 Not Applicable
163 Vaccination for Children of H&O and Their Parents Recruiting NCT03373656 Not Applicable
164 Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia Not yet recruiting NCT03922594
165 Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines Terminated NCT00138255
166 Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines Withdrawn NCT01738841

Search NIH Clinical Center for Rubella

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

The Foundational Model of Anatomy Ontology organs/tissues related to Rubella:

20
Skin

MalaCards organs/tissues related to Rubella:

42
Testes, Eye, Heart, Skin, T Cells, Brain, Lymph Node

Publications for Rubella

Articles related to Rubella:

(showing 3695, show less)
# Title Authors Year
1
Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'. ( 31062020 )
2019
2
Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. ( 30831578 )
2019
3
The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries. ( 30285537 )
2019
4
Last cases of rubella and congenital rubella syndrome in Spain, 1997-2016: The success of a vaccination program. ( 30454948 )
2019
5
Clinical manifestations of congenital rubella syndrome: A review of our experience in Vietnam. ( 30503658 )
2019
6
50 Years Ago in The Journal of Pediatrics: Maternal and Congenital Rubella before 1964: Frequency, Clinical Features, and Search for Isoimmune Phenomena. ( 30684990 )
2019
7
Comparison of two commercial ELISA kits for detection of rubella specific IgM in suspected congenital rubella syndrome cases and rubella IgG antibodies in a serosurvey of pregnant women. ( 30782464 )
2019
8
Congenital B-cell Acute Lymphoblastic Leukemia with Congenital Rubella Infection. ( 30806367 )
2019
9
Predicting congenital rubella syndrome in Japan, 2018-2019. ( 30807870 )
2019
10
Aniridia: A Rare Manifestation Of Congenital Rubella Syndrome. ( 30868799 )
2019
11
A case of immune-mediated type 1 diabetes mellitus due to congenital rubella ınfection. ( 30943684 )
2019
12
Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. ( 30814030 )
2019
13
Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. ( 30833160 )
2019
14
Will dual Japanese encephalitis and measles-rubella vaccination hinder measles and rubella eradication? ( 30833161 )
2019
15
Does Food Allergy Require Any Change in Measles-Mumps-Rubella Vaccination? ( 31104294 )
2019
16
Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. ( 30317494 )
2019
17
Antiviral immunity in chronic lymphocytic leukemia measured by anti-rubella antibody. ( 30659789 )
2019
18
Risk factors associated with accelerated rubella-IgG antibody loss in previously vaccinated,treatment-naïve juvenile Systemic Lupus Erythematosus patients: a prospective study. ( 30614217 )
2019
19
Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey. ( 30898393 )
2019
20
Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016. ( 30904317 )
2019
21
Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey. ( 30905529 )
2019
22
Rubella (German measles) revisited. ( 30967519 )
2019
23
Drivers and barriers for measles rubella vaccination campaign: A qualitative study. ( 31041218 )
2019
24
Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multi-site, rare event, distributed setting: Part 2 In-Depth Example of a re-analysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk. ( 31055178 )
2019
25
Measles-Rubella Campaign: Could Things Have Been Done Differently? ( 31064912 )
2019
26
Overcoming the pitfall of elimination due to different travel volumes: Estimation of the reproduction number for measles and rubella. ( 31075426 )
2019
27
Assessment of Economic Burden of Concurrent Measles and Rubella Outbreaks, Romania, 2011-2012. ( 31107215 )
2019
28
A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults. ( 31112277 )
2019
29
Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial. ( 30666071 )
2019
30
Relationship Between Media Coverage and Measles-Mumps-Rubella (MMR) Vaccination Uptake in Denmark: Retrospective Study. ( 30672743 )
2019
31
Measles and rubella seroimmunity in newly arrived adult immigrants in Sweden. ( 30676125 )
2019
32
Measles, mumps, and rubella: A cross-sectional study of susceptibility to vaccine-preventable diseases among young people in India. ( 30705481 )
2019
33
Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial. ( 30724658 )
2019
34
Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement. ( 30758772 )
2019
35
Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants. ( 30765170 )
2019
36
Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. ( 30765242 )
2019
37
Long-term protection against varicella with two-dose combination measles-mumps-rubella-varicella vaccine. ( 30765245 )
2019
38
The Efficacy and Safety of Intralesional Immunotherapy with Measles, Mumps, Rubella Virus Vaccine for the Treatment of Common Warts in Adults. ( 30775294 )
2019
39
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. ( 30785357 )
2019
40
The immunomodulatory effects of measles-mumps-rubella (MMR) vaccination on persistence of heterologous vaccine responses. ( 30791143 )
2019
41
Health Departments' Experience With Mumps Outbreak Response and Use of a Third Dose of Measles, Mumps, and Rubella Vaccine. ( 30807465 )
2019
42
Use of FTA Cards To Transport Throat Swabs and Oral Fluid Samples for Molecular Detection and Genotyping of Measles and Rubella Viruses. ( 30814262 )
2019
43
Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba. ( 30817853 )
2019
44
Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study. ( 30843921 )
2019
45
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. ( 30849175 )
2019
46
Successes and challenges for preventing measles, mumps and rubella by vaccination. ( 30852425 )
2019
47
Measles and rubella seroprevalence in a population of young adult blood donors, France 2013. ( 30869022 )
2019
48
Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. ( 30171797 )
2019
49
Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age. ( 30481110 )
2019
50
Revaccination With Measles-Mumps-Rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ( 29846533 )
2019
51
What are the beliefs and perceptions of practice nurses' influence about the uptake of the measles, mumps, and rubella vaccine?: An integrative literature review. ( 30109727 )
2019
52
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with rubella retinopathy. ( 29411259 )
2019
53
Decreased antibodies against rubella in previously vaccinated treatment-naïve childhood systemic lupus erythematous patients: a prospective case-control study. ( 29741129 )
2019
54
Adverse pregnancy outcomes among pregnant women with acute Rubella infections in Mwanza city, Tanzania. ( 30391418 )
2019
55
Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders. ( 30607663 )
2019
56
Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma. ( 30680653 )
2019
57
Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision. ( 30701339 )
2019
58
Validation of monoplex assays detecting antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, rubella virus and parvovirus B19 for incorporation into Multiplex Serology. ( 30703462 )
2019
59
Determination of rubella virus-specific humoral and cell-mediated immunity in pregnant women with negative or equivocal rubella-specific IgG in routine screening. ( 30711798 )
2019
60
Low anti-rubella antibody levels in public facilities staff in Tokyo. ( 30723000 )
2019
61
Evaluation of the Abbott ARCHITECT™ cytomegalovirus IgM/IgG, rubella IgM/IgG, and syphilis treponemal antibodies enzyme immunoassays in a mother and child health center population. ( 30738692 )
2019
62
Clinical Manifestations, Prognosis And Vaccination Status Of Patients With Rubella Virus-Associated Uveitis. ( 30771336 )
2019
63
Antifungal Phenylpropanoid Glycosides from Lippia rubella. ( 30817148 )
2019
64
First report of the genomic characterization of rubella viruses circulating in Cameroon. ( 30822356 )
2019
65
A case of adult rubella in Japan. ( 30825652 )
2019
66
Erratum: Diagnosis of rubella virus using antigen-conjugated Au@Pt nanorods as nanozyme probe [Corrigendum]. ( 30863060 )
2019
67
Transposable elements drive rapid phenotypic variation in Capsella rubella. ( 30877258 )
2019
68
Rubella outbreak in the school children, Addis Ababa, Ethiopia: February-April 2018. ( 30885148 )
2019
69
Enhancing preparedness against rubella at the workplace: proactive prevention efforts by the Tokyo Metropolitan Government. ( 30918146 )
2019
70
The risk factors of exposure to rubella among pregnant women in Zaria 2013. ( 30949283 )
2019
71
Perception of rubella risk in pregnancy: an epidemiological survey on a sample of pregnant women. ( 30994165 )
2019
72
Comparison of the LIAISON®XL and ARCHITECT IgG, IgM, and IgG avidity assays for the diagnosis of Toxoplasma, cytomegalovirus, and rubella virus infections. ( 30994178 )
2019
73
The seroprevalence of Rubella in pregnant women in Turkey: a meta-analysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results. ( 31019842 )
2019
74
Modelling a Supplementary Vaccination Program of Rubella Using the 2012⁻2013 Epidemic Data in Japan. ( 31027277 )
2019
75
"Noninfectious" Cutaneous Granulomas in Primary Immunodeficiency Patients and Association With Rubella Virus Vaccine Strain. ( 31070095 )
2019
76
Awareness and Factors Associated with Health Care Worker's Knowledge on Rubella Infection: A Study after the Introduction of Rubella Vaccine in Tanzania. ( 31091685 )
2019
77
Rubella Vaccination Coverage Among Women of Childbearing Age in Vietnam. ( 31100981 )
2019
78
Progress Toward Rubella and Congenital Rubella Syndrome Control - South-East Asia Region, 2000-2016. ( 29851943 )
2018
79
Congenital rubella syndrome surveillance in South Africa using a sentinel site approach: a cross-sectional study. ( 30203002 )
2018
80
Sentinel Surveillance for Congenital Rubella Syndrome - India, 2016-2017. ( 30212443 )
2018
81
Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic review of existing literature and transmission modelling of sero-prevalence studies. ( 30289078 )
2018
82
Hospital based surveillance of congenital rubella syndrome cases in the pre-vaccine era in Amhara Regional State, Ethiopia: A base line information for the country. ( 30419036 )
2018
83
Congenital Rubella Syndrome in The African Region - Data from Sentinel Surveillance. ( 30957103 )
2018
84
Two Imported Cases of Congenital Rubella Syndrome and Infection-Control Challenges in New York State, 2013-2015. ( 28510706 )
2018
85
Congenital rubella syndrome: an unusual cause of neonatal fulminant hepatic failure. ( 28678001 )
2018
86
Clinical profile of congenital rubella syndrome in Yogyakarta, Indonesia. ( 29068106 )
2018
87
Congenital rubella syndrome: A brief review of public health perspectives. ( 29512566 )
2018
88
Imported Congenital Rubella Syndrome, United States, 2017. ( 29553333 )
2018
89
Rubella infection in pregnancy and congenital rubella in United Kingdom, 2003 to 2016. ( 29766840 )
2018
90
Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016. ( 29454516 )
2018
91
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. ( 29576304 )
2018
92
Seroprevalence of Maternal and Cord Antibodies Specific for Diphtheria, Tetanus, Pertussis, Measles, Mumps and Rubella in Shunyi, Beijing. ( 30158679 )
2018
93
Acute Encephalitis with Atypical Presentation of Rubella in Family Cluster, India. ( 30226166 )
2018
94
Seroprevalence data at a private teaching hospital in Kenya: An examination of Toxoplasma gondii, cytomegalovirus, rubella, hepatitis A, and Entamoeba histolytica. ( 30325924 )
2018
95
Active immunization status against measles, mumps, rubella, hepatitis B in internationally adopted children, surveyed at the university hospital of Palermo, Sicily. ( 30062371 )
2018
96
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
97
TORCH (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus) screening of small for gestational age and intrauterine growth restricted neonates: efficacy study in a single institute in Korea. ( 29713357 )
2018
98
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
99
Descriptive Study of Rubella Titer Status in Infertility Patients. ( 30742748 )
2018
100
Seroprevalance of Rubella in an Urban Infertility Clinic - Observations and Challenges Ahead. ( 30787525 )
2018
101
Measles, mumps, and rubella vaccine in genital warts: A case report of two patients. ( 30623187 )
2018
102
Local and distal involution of recalcitrant warts after a single intralesional dose of measles, mumps, and rubella vaccine. ( 30677806 )
2018
103
Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. ( 30118386 )
2018
104
Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: Post-hoc exploratory analysis of results from a matched-cohort study. ( 30131195 )
2018
105
Dual-chamber injection device for measles-rubella vaccine: The potential impact of introducing varying sizes of the devices in 3 countries. ( 30146404 )
2018
106
Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection. ( 30209129 )
2018
107
Integrating Blood Collection within Household Surveys: Lessons Learned from Nesting a Measles and Rubella Serological Survey within a Post-Campaign Coverage Evaluation Survey in Southern Province, Zambia. ( 30277204 )
2018
108
Vaccination Status and Antibody Titers against Rubella and Measles among Japanese Female College Students Majoring in Childcare between 2015 and 2018. ( 30282845 )
2018
109
Cost of Public Health Response and Outbreak Control With a Third Dose of Measles-Mumps-Rubella Vaccine During a University Mumps Outbreak-Iowa, 2015-2016. ( 30302350 )
2018
110
Measles-Rubella vaccination campaign: A trust deficit? ( 30306966 )
2018
111
Global landscape of measles and rubella surveillance. ( 30318167 )
2018
112
To the editor: Response to Willame, et al., published in Vaccine 35 (2017) 5551-5558, entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review". ( 30348361 )
2018
113
Reply to Lee et al.'s letter to the editor pertaining to our publication entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review". ( 30348362 )
2018
114
Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm. ( 30388799 )
2018
115
Measles and Rubella Seroprevalence in Mother-Infant Pairs in Rural Nepal and the United States: Pre- and Post-Elimination Populations. ( 30403166 )
2018
116
A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques. ( 29701813 )
2018
117
Recognizing Measles, Mumps, and Rubella in the Emergency Department. ( 29715253 )
2018
118
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. ( 29785233 )
2018
119
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. ( 29792546 )
2018
120
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. ( 29792776 )
2018
121
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. ( 29865869 )
2018
122
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study. ( 29902133 )
2018
123
Social capital, trust in health information, and acceptance of Measles-Rubella vaccination campaign in Tamil Nadu: A case-control study. ( 29943738 )
2018
124
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. ( 29945697 )
2018
125
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016. ( 29965975 )
2018
126
Measles-Rubella Supplementary Immunization Activity Readiness Assessment - India, 2017-2018. ( 29975677 )
2018
127
Strengthening routine immunization through measles-rubella elimination. ( 30041881 )
2018
128
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial. ( 30104117 )
2018
129
Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults. ( 30107992 )
2018
130
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
131
Voluntary termination of pregnancy: An opportunity for Measles, Mumps and Rubella vaccination in an Italian healthcare local unit. ( 29261361 )
2018
132
Measles and Rubella Global Strategic Plan 2012-2020 midterm review. ( 29307367 )
2018
133
Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary. ( 29307368 )
2018
134
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
135
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
136
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. ( 29420120 )
2018
137
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. ( 29424220 )
2018
138
Waning immunity of one-dose measles-mumps-rubella vaccine to mumps in children from kindergarten to early school age: a prospective study. ( 29478347 )
2018
139
Geographic Spread of Influenza under the Influence of Community Population Size, Which Differed from That of Measles and Rubella. ( 29491244 )
2018
140
Evaluation of a Mobile Phone-Based Intervention to Increase Parents' Knowledge About the Measles-Mumps-Rubella Vaccination and Their Psychological Empowerment: Mixed-Method Approach. ( 29514772 )
2018
141
Evaluation of measles and rubella integrated surveillance system in Apulia region, Italy, 3 years after its introduction. ( 29532766 )
2018
142
Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. ( 29562334 )
2018
143
Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine. ( 29596472 )
2018
144
Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination. ( 29614919 )
2018
145
2017 Measles-Rubella Vaccination Campaign in India. ( 29619155 )
2018
146
Mumps Outbreak in a Highly Vaccinated University-Affiliated Setting Before and After a Measles-Mumps-Rubella Vaccination Campaign-Iowa, July 2015-May 2016. ( 29020324 )
2018
147
Measles and rubella eradication. ( 29183733 )
2018
148
Progress and challenges in measles and rubella elimination in the WHO European Region. ( 28651838 )
2018
149
An Intraocular Inflammatory Profile of Rubella Associated Uveitis. ( 29370571 )
2018
150
Rubella antibodies in cord blood sera in Portugal: association with maternal age and vaccination status. ( 29458448 )
2018
151
Standardization of rubella immunoassays. ( 29486385 )
2018
152
Rubella seroprevalence among pregnant women in Beijing, China. ( 29544450 )
2018
153
Epidemiological profile and progress toward rubella elimination in China. 10 years after nationwide introduction of rubella vaccine. ( 29550193 )
2018
154
Isolation of infectious Zika virus from a urine sample cultured in SIRC cells from a patient suspected of having rubella virus. ( 29557985 )
2018
155
Assessing the Effectiveness and Cost-Benefit of Test-and-Vaccinate Policy for Supplementary Vaccination against Rubella with Limited Doses. ( 29565821 )
2018
156
Seroprevalence of antibodies against varicella zoster virus and rubella virus among newly recruited expatriate healthcare workers: a cross-sectional study. ( 29567844 )
2018
157
Australian rubella serosurvey 2012-2013: On track for elimination? ( 29661586 )
2018
158
Seroprevalence of Zika virus and Rubella virus IgG among blood donors in Rwanda and in Sweden. ( 29663453 )
2018
159
Parallel Evolution of Common Allelic Variants Confers Flowering Diversity in Capsella rubella. ( 29764984 )
2018
160
Seroprevalence of HIV, HTLV, CMV, HBV and rubella virus infections in pregnant adolescents who received care in the city of Belém, Pará, Northern Brazil. ( 29769062 )
2018
161
Response to third rubella vaccine dose. ( 29771601 )
2018
162
Multimodal imaging in serologically confirmed Rubella retinopathy. ( 29934649 )
2018
163
Rubella Viruses Shift Cellular Bioenergetics to a More Oxidative and Glycolytic Phenotype with a Strain-Specific Requirement for Glutamine. ( 29950419 )
2018
164
Towards rubella elimination in Japan. ( 29976516 )
2018
165
Epidemiology of rubella infection and genotyping of rubella virus in Cote d'Ivoire, 2012-2016. ( 29984523 )
2018
166
Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. ( 30037665 )
2018
167
Sero-epidemiological evaluation of rubella immunity among pre-marriage women in Iran. ( 30047822 )
2018
168
No. 203-Rubella in Pregnancy. ( 30103885 )
2018
169
Impact of Maternal BMI on Rubella Nonimmunity at Antenatal Screening. ( 30120821 )
2018
170
Rubella Virus Genotype 1E in Travelers Returning to Japan from Indonesia, 2017. ( 30124420 )
2018
171
Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers. ( 30144493 )
2018
172
Rubella virus infections and immune status among pregnant women before the introduction of rubella vaccine in Amhara Regional State, Ethiopia. ( 30165188 )
2018
173
Diagnosis of rubella virus using antigen-conjugated Au@Pt nanorods as nanozyme probe. ( 30197515 )
2018
174
Alterations in Cell Mechanics by Actin Cytoskeletal Changes Correlate with Strain-Specific Rubella Virus Phenotypes for Cell Migration and Induction of Apoptosis. ( 30217036 )
2018
175
High BMI: A New Determinant of Impaired Rubella Immunity During Pregnancy? ( 30226004 )
2018
176
Comparison of three immunoassays for determination of immunity to rubella virus in healthcare workers. ( 30237054 )
2018
177
Rubella immunity and serum perfluoroalkyl substances: Sex and analytic strategy. ( 30248109 )
2018
178
Rubella Virus Strain-Associated Differences in the Induction of Oxidative Stress Are Independent of Their Interferon Activation. ( 30282907 )
2018
179
The Relationship between Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and the Rubella Virus. ( 30284774 )
2018
180
Notes from the Field: Rubella Infection in an Unvaccinated Pregnant Woman - Johnson County, Kansas, December 2017. ( 30307903 )
2018
181
Reconstructing the transmission dynamics of rubella in Japan, 2012-2013. ( 30332469 )
2018
182
Vaccine Rubella: A Rare Cause of Post-transplant Hematopoietic Death, but a Major Public Health Problem. ( 30349846 )
2018
183
The Prevalence of Anti-Rubella Antibodies in Pregnant Women of Turkey, Results of 94508 Patients in a Tertiary Referral Center. ( 30381819 )
2018
184
Rubella in Poland in 2016 ( 30394039 )
2018
185
Sero-prevalence of rubella among pregnant women in India, 2017. ( 30448333 )
2018
186
Correlation Analysis of Rubella Incidence and Meteorological Variables Based on Chinese Medicine Theory of Yunqi. ( 30467697 )
2018
187
No. 368-RUBELLA IN PREGNANCY. ( 30527073 )
2018
188
Clinical value of enzyme immunoassay detecting rubella-specific immunoglobulin M immediately after the disease onset. ( 30549103 )
2018
189
Rubella Retinopathy. ( 30578518 )
2018
190
Association of Ocular Inflammation and Rubella Virus Persistence. ( 30589932 )
2018
191
Talk to Patients About: Rubella. ( 30605557 )
2018
192
The Impact of Recent Rubella Vaccine Introduction in 5 Countries in The African Region. ( 30957104 )
2018
193
A Prospective OCT Study of Rubella Retinopathy. ( 31047196 )
2018
194
Myelin Oligodendrocyte Glycoprotein-Independent Rubella Infection of Keratinocytes and Resistance of First-Trimester Trophoblast Cells to Rubella Virus In Vitro. ( 29300335 )
2018
195
Rubella natural immunity among adolescent girls in Tanzania: the need to vaccinate child bearing aged women. ( 29298693 )
2018
196
Epidemiological changes in rubella IgG antibody levels detected in antenatal women from a retrospective rubella seroprevalence study. ( 29209940 )
2018
197
Rubella vaccination in India: identifying broad consequences of vaccine introduction and key knowledge gaps. ( 29198212 )
2018
198
A novel cell-based high throughput assay to determine neutralizing antibody titers against circulating strains of rubella virus. ( 29191395 )
2018
199
Rubella Vaccine-Reply. ( 29159369 )
2018
200
Rubella Vaccine-A Tale of Appropriate Caution and Remarkable Success. ( 29159364 )
2018
201
Large choroidal excavation in a patient with rubella retinopathy. ( 29077180 )
2018
202
Prevalence of Rubella Antibodies Among Children in the Democratic Republic of the Congo. ( 28746265 )
2018
203
Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. ( 27810866 )
2017
204
Fetal and neonatal abnormalities due to congenital rubella syndrome: a review of literature. ( 27002428 )
2017
205
The end of measles and congenital rubella: an achievable dream? ( 28067934 )
2017
206
Hospital-based surveillance of congenital rubella syndrome in Indonesia. ( 28091778 )
2017
207
50 Years Ago in The Journal of Pediatrics: Cerebral Lesions in Congenital Rubella Syndrome. ( 28129869 )
2017
208
Sensory defects and developmental delay among children with congenital rubella syndrome. ( 28406248 )
2017
209
Underreporting of congenital rubella in Italy, 2010-2014. ( 28551878 )
2017
210
Clinically Confirmed Congenital Rubella Syndrome: The Role of Echocardiography. ( 28579716 )
2017
211
Newborn with transient macular rash and thrombocytopenia. Skeletal manifestations of congenital rubella syndrome. ( 28600621 )
2017
212
Erratum to: Underreporting of congenital rubella in Italy, 2010-2014. ( 28695269 )
2017
213
An update on epidemiology of congenital rubella syndrome: how far from the World Health Organization goals? ( 28728344 )
2017
214
Progress in Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2000-2016. ( 29145358 )
2017
215
Progress in rubella and congenital rubella syndrome control and elimination – worldwide, 2000–2016. ( 29148274 )
2017
216
An infant with congenital rubella syndrome in developing India. ( 29184005 )
2017
217
Lacrimal drainage anomalies in congenital rubella syndrome. ( 29184387 )
2017
218
The burden of congenital rubella syndrome in the Philippines: results from a retrospective assessment. ( 29184700 )
2017
219
Multimodal Imaging of Congenital Rubella Retinopathy. ( 31047452 )
2017
220
Maternal rubella immunity status and pre-eclampsia. ( 28370838 )
2017
221
30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study. ( 28259562 )
2017
222
Rubella, herpes simplex virus type 2 and preeclampsia. ( 28747200 )
2017
223
Pivoting from polio eradication to measles and rubella elimination: a transition that makes sense both for children and immunization program improvement. ( 29296145 )
2017
224
Micro-planning in a wide age range measles rubella (MR) campaign using mobile phone app, a case of Kenya, 2016. ( 29296151 )
2017
225
Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine. ( 29308410 )
2017
226
Epstein-Barr Virus, but Not Cytomegalovirus, Latency Accelerates the Decay of Childhood Measles and Rubella Vaccine Responses-A 10-Year Follow-up of a Swedish Birth Cohort. ( 29312344 )
2017
227
A New Combined Vaccine Against Measles, Mumps, Rubella and Varicella in India. ( 29317560 )
2017
228
Can Norway be kept free from rubella and measles? ( 28828847 )
2017
229
Expansion of Surveillance for Vaccine-preventable Diseases: Building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network Platforms. ( 28838191 )
2017
230
Transitioning Lessons Learned and Assets of the Global Polio Eradication Initiative to Global and Regional Measles and Rubella Elimination. ( 28838195 )
2017
231
Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal. ( 28838201 )
2017
232
The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014. ( 28850604 )
2017
233
Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. ( 28855159 )
2017
234
Measles, Rubella and Varicella IgG Seroprevalence in a Large Refugee Cohort in Germany in 2015: A Cross-Sectional Study. ( 28875465 )
2017
235
Pain caused by measles, mumps, and rubella vaccines: A systematic literature review. ( 28893478 )
2017
236
Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach. ( 29037086 )
2017
237
County-level assessment of United States kindergarten vaccination rates for measles mumps rubella (MMR) for the 2014-2015 school year. ( 29037574 )
2017
238
Infection of iPSC Lines with Miscarriage-Associated Coxsackievirus and Measles Virus and Teratogenic Rubella Virus as a Model for Viral Impairment of Early Human Embryogenesis. ( 29043768 )
2017
239
Measles, mumps, rubella, and varicella among service members and other beneficiaries of the Military Health System, 2010-2016. ( 29077422 )
2017
240
Consequences of perinatal infections with rubella, measles, and mumps. ( 29175731 )
2017
241
Notes from the Field: Complications of Mumps During a University Outbreak Among Students Who Had Received 2 Doses of Measles-Mumps-Rubella Vaccine - Iowa, July 2015-May 2016. ( 28406886 )
2017
242
Challenges of measles and rubella laboratory diagnostic in the era of elimination. ( 28412379 )
2017
243
Eliminating measles and rubella in Europe. ( 28412385 )
2017
244
Modeling and Managing the Risks of Measles and Rubella: A Global Perspective Part II. ( 28471528 )
2017
245
An Appeal to all Pediatricians and Members of Indian Academy of Pediatrics for the Measles-Rubella Campaign. ( 28474584 )
2017
246
Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin. ( 28481690 )
2017
247
Missed Opportunities for Measles, Mumps, Rubella Vaccination Among Departing U.S. Adult Travelers Receiving Pretravel Health Consultations. ( 28505632 )
2017
248
Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases. ( 28561947 )
2017
249
Global and national laboratory networks support high quality surveillance for measles and rubella. ( 28582561 )
2017
250
Media and Measles-Rubella Vaccination Campaign - Musings from Pondicherry. ( 28601859 )
2017
251
The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study. ( 28604255 )
2017
252
Universal measles-mumps-rubella vaccination to new recruits and the incidence of mumps in the military. ( 28633890 )
2017
253
Mumps, Measles, and Rubella Vaccine for the Treatment of a Recalcitrant Subungual Wart. ( 28709617 )
2017
254
Molecular surveillance of measles and rubella in the WHO European Region: new challenges in the elimination phase. ( 28712666 )
2017
255
Utilization and impact of European immunization week to increase measles, mumps, rubella vaccine uptake in Austria in 2016. ( 28797728 )
2017
256
Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. ( 28806450 )
2017
257
Measles and Rubella Seroprevalence Among HIV-infected and Uninfected Zambian Youth. ( 27879554 )
2017
258
Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )
2017
259
Measles and rubella elimination in the WHO Region for Europe: progress and challenges. ( 28111293 )
2017
260
Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. ( 28231366 )
2017
261
Roadmap to elimination standard measles and rubella surveillance. ( 28262010 )
2017
262
Factors influencing uptake of measles, mumps and rubella (MMR) immunization in site-dwelling Gypsy, Roma and Traveller (G&T) communities: a qualitative study of G&T parents' beliefs and experiences. ( 28271558 )
2017
263
Trend of measles, mumps, and rubella incidence following the measles-rubella catch up vaccination in the Republic of Korea, 2001. ( 28303592 )
2017
264
Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination. ( 28318190 )
2017
265
Evaluation of Measles-Mumps-Rubella Vaccination Among Newly Arrived Refugees. ( 28323479 )
2017
266
Acute Bilateral Photoreceptor Degeneration in an Infant After Vaccination Against Measles and Rubella. ( 28358967 )
2017
267
Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial. ( 28362563 )
2017
268
Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study. ( 28368471 )
2017
269
Epidemiology of rubella infection in Cameroon: a 7-year experience of measles and rubella case-based surveillance, 2008-2014. ( 28389483 )
2017
270
Active safety monitoring of measles-mumps-rubella vaccine in the National Immunisation Programme of Sri Lanka ( 28390326 )
2017
271
A Moral Imperative to Eradicate Measles, Rubella. ( 30036003 )
2017
272
Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies. ( 27253624 )
2017
273
Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany. ( 27780480 )
2017
274
Scale-Free Distribution of Local Infection Clusters of Measles, Rubella, Syphilis, and HIV/AIDS: Correlation with Scale-Free Distribution of Municipality Population by Size. ( 27169948 )
2017
275
Spectral Domain-Optical Coherence Tomography Findings in Unilateral Rubella Retinopathy. ( 27579589 )
2017
276
A sensitive one-step TaqMan amplification approach for detection of rubella virus clade I and II genotypes in clinical samples. ( 27807657 )
2017
277
Rubella Immunity in Pregnant Native Taiwanese and Immigrants from Asian Countries. ( 27895276 )
2017
278
Antiviral activity of hemolymph of Podalia against rubella virus. ( 27896559 )
2017
279
Rubella outbreak and outbreak management in a school setting, China, 2014. ( 27905834 )
2017
280
Susceptibility of Rubella Among Pregnant Women Attending the Antenatal Clinic in a Tertiary Care Hospital, Jabalpur, Central India. ( 27925863 )
2017
281
Genetic diversity of currently circulating rubella viruses: a need to define more precise viral groups. ( 27959771 )
2017
282
FUNDUS AUTOFLUORESCENCE IN RUBELLA RETINOPATHY: Correlation With Photoreceptor Structure and Function. ( 28005720 )
2017
283
Rubella in Sub-Saharan Africa and sensorineural hearing loss: a case control study. ( 28143602 )
2017
284
External Quality Assessment for Rubella Virus RNA Detection Using Armored RNA in China. ( 28182341 )
2017
285
Global seroprevalence of rubella among pregnant and childbearing age women: a meta-analysis. ( 28204465 )
2017
286
Rubella Seromarkers and Determinants of Infection among Tanzanian Children and Adolescents in Prevaccination Era: Are We in the Right Track? ( 28217265 )
2017
287
Lack of immunity against rubella among Italian young adults. ( 28270106 )
2017
288
Introducing rubella vaccine into the national immunisation schedule. ( 28303838 )
2017
289
Screening for potential susceptibility to rubella in an antenatal population: A multivariate analysis. ( 28370103 )
2017
290
Dynamic Change in Variation of Rubella Viruses Circulating in Mainland China. ( 30702824 )
2017
291
SEROPREVALENCE OF RUBELLA ANTIBODIES AMONG TURKISH AND FOREIGN WOMEN IN TURKEY. ( 29644821 )
2017
292
Seroprevalence of Rubella and Cytomegalia in Young Women from Biała Podlaska District. ( 29319529 )
2017
293
Progress towards rubella elimination after implementation of rubella immunization for over 20 years in Shandong province, China. ( 29269776 )
2017
294
Rubella in Poland in 2015 ( 29181958 )
2017
295
Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology. ( 29145521 )
2017
296
Rubella Seromarkers among Children and Adolescent. ( 29114380 )
2017
297
Both sphingomyelin and cholesterol in the host cell membrane are essential for Rubella virus entry. ( 29070689 )
2017
298
Rubella virus infection and associated factors among pregnant women attending the antenatal care clinics of public hospitals in Hawassa City, Southern Ethiopia: a cross-sectional study. ( 28982820 )
2017
299
Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency. ( 28974385 )
2017
300
Rubella Seropositivity in Pregnant Women After Vaccination Campaign in Brazil's Federal District. ( 28972455 )
2017
301
Comparison of rubella immunization rates in immigrant and Italian women of childbearing age: Results from the Italian behavioral surveillance system PASSI (2011-2015). ( 28968403 )
2017
302
Complete Genome Sequence of a Genotype 2B Rubella Virus Isolated in South Korea in 2015. ( 28935733 )
2017
303
Erratum to: lack of immunity against rubella among Italian young adults. ( 28927377 )
2017
304
Analysis of VSV pseudotype virus infection mediated by rubella virus envelope proteins. ( 28912595 )
2017
305
Impact of the two-dose rubella vaccination regimen on incidence of rubella seronegativity in gravidae aged 25 years and younger. ( 28854204 )
2017
306
Molecular Epidemiology of Rubella Virus Strains Detected Around the Time of the 2012-2013 Epidemic in Japan. ( 28848523 )
2017
307
Adult Rubella in a Returned Traveler. ( 28768990 )
2017
308
Sociodemographic and economic characteristics of susceptibility to rubella among women preparing for pregnancy in rural China. ( 28739423 )
2017
309
Rubella sero-prevalence among children in Kilimanjaro region: a community based study prior to the introduction of rubella vaccine in Tanzania. ( 28732540 )
2017
310
Rubella Surveillance and Diagnostic Testing among a Low-Prevalence Population, New York City, 2012-2013. ( 28701468 )
2017
311
Regulation of FATTY ACID ELONGATION1 expression and production in Brassica oleracea and Capsella rubella. ( 28674753 )
2017
312
Seroprevalence of Toxoplasma gondii, Rubella virus and Cytomegalovirus among pregnant women and the importance of avidity assays. ( 28674718 )
2017
313
Rubella and Zika Vaccine Research-A Cautionary Tale About Caution. ( 28654956 )
2017
314
Prior pregnancy and antenatal rubella sero-negativity-evidence of persistent maternal immunologic alteration? ( 28653441 )
2017
315
History repeats itself in Japan: Failure to learn from rubella epidemic leads to failure to provide the HPV vaccine. ( 28604161 )
2017
316
Rubella antibodies in Australian immunoglobulin products. ( 28604142 )
2017
317
Preliminary multiplex microarray IgG immunoassay for the diagnosis of toxoplasmosis and rubella. ( 28591403 )
2017
318
Assembly, maturation and three-dimensional helical structure of the teratogenic rubella virus. ( 28575072 )
2017
319
Study of rubella candidate vaccine based on a structurally modified plant virus. ( 28511994 )
2017
320
Acute Rubella Virus Infection among Women with Spontaneous Abortion in Mwanza City, Tanzania. ( 28511456 )
2017
321
Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. ( 28483193 )
2017
322
Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008-2011. ( 28461066 )
2017
323
Rubella virus immunization status in preconception period among Chinese women of reproductive age: A nation-wide, cross-sectional study. ( 28456531 )
2017
324
Rubella Seroprevalence and real-time PCR detection of RUBV among Congolese pregnant women. ( 28381214 )
2017
325
Rubella Virus-associated Anterior Uveitis in a Vaccinated Patient: A Case Report. ( 24945813 )
2016
326
Aseptic meningitis after measles-mumps-rubella (MMR) vaccination. ( 27181175 )
2016
327
Rubella cataract and retinopathy. ( 27288206 )
2016
328
Maternal and Congenital cytomegalovirus infection and zero rubella IgM prevalence in newborns in St.Paul's Hospital Millennium Medical College. ( 27769314 )
2016
329
Systematic Review of the Manifestations of Congenital Rubella Syndrome in Infants and Characterization of Disability-Adjusted Life Years (DALYs). ( 25115193 )
2016
330
Epidemiology of rubella and congenital rubella syndrome in Japan before 1989. ( 26469722 )
2016
331
Shedding of Rubella Virus among Infants with Congenital Rubella Syndrome Born in Tokyo, Japan, 2013-2014. ( 26567831 )
2016
332
Congenital rubella syndrome with death from interstitial pneumonia. ( 26840886 )
2016
333
Localization of Viral Antigens Improves Understanding of Congenital Rubella Syndrome Pathophysiology. ( 26870811 )
2016
334
Immunolocalization and Distribution of Rubella Antigen in Fatal Congenital Rubella Syndrome. ( 26870820 )
2016
335
Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review. ( 26962867 )
2016
336
Serological evidence of acute rubella infection among under-fives in Mwanza: a threat to increasing rates of congenital rubella syndrome in Tanzania. ( 27225802 )
2016
337
Congenital Rubella Syndrome: A Case Report on Changes in Viral Load and Rubella Antibody Titers. ( 27244797 )
2016
338
Is birth cohort 1985/9-1990/8 a susceptibility window for congenital rubella syndrome in Taiwan? ( 27343317 )
2016
339
Psychiatric manifestations of congenital rubella syndrome: A case report and review of literature. ( 27606025 )
2016
340
Congenital Rubella. ( 27732820 )
2016
341
An outbreak investigation of congenital rubella syndrome in Solomon Islands, 2013. ( 27757248 )
2016
342
Using the two-source capture-recapture method to estimate the incidence and case ascertainment of congenital rubella syndrome in Australia, 1993-2013. ( 27757254 )
2016
343
Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy. ( 27866768 )
2016
344
A case of congenital rubella syndrome and infection in South-East London in 2015: prevention, diagnosis, and the public health response. ( 27884915 )
2016
345
Vaccination in secondary school students expedites rubella control and prevents congenital rubella syndrome. ( 27899091 )
2016
346
Rubella and Congenital Rubella Syndrome in the Philippines: A Systematic Review. ( 28115948 )
2016
347
Measles-Mumps-Rubella vaccine for children with egg allergy: Is admission for inpatient vaccination necessary? ( 27770112 )
2016
348
Vaccine-preventable diseases in pediatric patients: a review of measles, mumps, rubella, and varicella [digest]. ( 28745854 )
2016
349
Humoral immunity to tetanus, measles and rubella in children with acute lymphoblastic leukemia after chemotherapy. ( 27869413 )
2016
350
Vaccine-Preventable Diseases In Pediatric Patients: A Review Of Measles, Mumps, Rubella, And Varicella. ( 27893360 )
2016
351
Mumps, measles and rubella vaccination in children with PFAPA syndrome. ( 27997341 )
2016
352
The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy. ( 27423382 )
2016
353
Anti-rubella, Mumps and Measles IgG Antibodies in Medical Students of Tehran University. ( 27424140 )
2016
354
Modeling and Managing the Risks of Measles and Rubella: A Global Perspective, Part I. ( 27424287 )
2016
355
Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015. ( 27449329 )
2016
356
Mumps Outbreak at a University and Recommendation for a Third Dose of Measles-Mumps-Rubella Vaccine - Illinois, 2015-2016. ( 27467572 )
2016
357
Mumps antibody in the Thai population 17 years after the universal measles mumps rubella vaccination program. ( 27482805 )
2016
358
Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh. ( 27519586 )
2016
359
Considerable decrease of antibody titers against measles, mumps, and rubella in preschool children from an e-waste recycling area. ( 27591526 )
2016
360
Persistence and Half-lives of Anti-measles and Anti-rubella Antibodies in Japanese Hospital Workers: A Longitudinal Study. ( 27629951 )
2016
361
Epidemiology of primary rubella infection in the Central African Republic: data from measles surveillance, 2007-2014. ( 27659859 )
2016
362
Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants. ( 27822935 )
2016
363
Laboratory confirmation of rubella infection in suspected measles cases. ( 27018071 )
2016
364
Intralesional mumps, measles and rubella vaccine in the treatment of cutaneous warts. ( 27088951 )
2016
365
High levels of susceptibility to measles, mumps and rubella (MMR) in HIV-infected individuals in Ireland. ( 27118245 )
2016
366
Measles & rubella outbreaks in Maharashtra State, India. ( 27121521 )
2016
367
Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand. ( 27138005 )
2016
368
Global Measles and Rubella Laboratory Network Support for Elimination Goals, 2010-2015. ( 27148917 )
2016
369
A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process. ( 27149048 )
2016
370
Global measles and rubella laboratory network support for elimination goals, 2010–2015. ( 27156255 )
2016
371
Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. ( 27163657 )
2016
372
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman. ( 27195163 )
2016
373
Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009. ( 27254037 )
2016
374
Evolution and Use of Dynamic Transmission Models for Measles and Rubella Risk and Policy Analysis. ( 27277138 )
2016
375
Influences on immunization rates: Vaccination coverage of mumps, measles, rubella and varicella before and after the STIKO intervention 2011 - A retrospective study. ( 27318420 )
2016
376
A review of testing used in seroprevalence studies on measles and rubella. ( 27340096 )
2016
377
A 16-year review of seroprevalence studies on measles and rubella. ( 27340097 )
2016
378
Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. ( 27364568 )
2016
379
Seroprevalence of Antibodies against Measles, Rubella and Varicella among Asylum Seekers Arriving in Lower Saxony, Germany, November 2014-October 2015. ( 27376309 )
2016
380
Immunity of nursing students to measles, mumps, rubella, and varicella in Yozgat, Turkey. ( 26442461 )
2016
381
A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy. ( 26528829 )
2016
382
Prevalence and genotypic characterization of Human Parvovirus B19 in children with measles- and rubella-like illness in Iran. ( 26538067 )
2016
383
Effect of socioeconomic deprivation on uptake of measles, mumps and rubella vaccination in Liverpool, UK over 16 years: a longitudinal ecological study. ( 26542197 )
2016
384
Measles and Rubella: Scale Free Distribution of Local Infection Clusters. ( 26567836 )
2016
385
Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. ( 26597262 )
2016
386
Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 Months During a Measles Outbreak in The Netherlands in 2013-2014. ( 26690343 )
2016
387
Evaluation of measles-rubella vaccination for mothers in early puerperal phase. ( 26801065 )
2016
388
Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial. ( 26823338 )
2016
389
The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study. ( 26852723 )
2016
390
Slow Progress In Finalizing Measles And Rubella Elimination In The European Region. ( 26858387 )
2016
391
Combining Global Elimination Of Measles And Rubella With Strengthening Of Health Systems In Developing Countries. ( 26858388 )
2016
392
Chance Isolation of Non-Pathogenic Vaccine-Derived Measles and Rubella Viruses from Children with Acute Respiratory Infections. ( 26902222 )
2016
393
Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months. ( 26908733 )
2016
394
Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India. ( 26910764 )
2016
395
Synthesis of Evidence to Characterize National Measles and Rubella Exposure and Immunization Histories. ( 26249328 )
2016
396
The Costs and Valuation of Health Impacts of Measles and Rubella Risk Management Policies. ( 26249331 )
2016
397
Systematic Review of Measles and Rubella Serology Studies. ( 26077609 )
2016
398
Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions. ( 25545778 )
2016
399
Seroprevalence of measles, mumps, rubella, and varicella amongphysicians and nurses in Jordan. ( 27513228 )
2016
400
Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal. ( 27488930 )
2016
401
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5α-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
402
Analysis of the temperature sensitivity of Japanese rubella vaccine strain TO-336.vac and its effect on immunogenicity in the guinea pig. ( 26878651 )
2016
403
Urine Pregnancy Test before Rubella Vaccination among Reproductive Age Females: An Observation. ( 26883859 )
2016
404
Well begun is half done: Rubella virus perturbs autophagy signaling, thereby facilitating the construction of viral replication compartments. ( 26968901 )
2016
405
Maternal Zika infection: like rubella but worse. ( 27119589 )
2016
406
Introduction of rubella-containing-vaccine to Madagascar: implications for roll-out and local elimination. ( 27122178 )
2016
407
Calcium-Dependent Rubella Virus Fusion Occurs in Early Endosomes. ( 27122589 )
2016
408
Assessing Immunity to Rubella Virus: a Plea for Standardization of IgG (Immuno)assays. ( 27147722 )
2016
409
Where to Now for Standardization of Anti-Rubella Virus IgG Testing. ( 27170018 )
2016
410
Rubella immunity among pregnant women aged 15-44 years, Namibia, 2010. ( 27196370 )
2016
411
Evaluation of sensitivity of TaqMan RT-PCR for rubella virus detection in clinical specimens. ( 27243209 )
2016
412
Rubella screening cessation. ( 27290870 )
2016
413
Seroepidemiology of Rubella in Mozambique, 2006-2014: Implications for Rubella Immunization in Settings With High Fertility Rates. ( 27294311 )
2016
414
Erratum to: Serological makers of rubella infection in Africa in the pre vaccination era: a systematic review. ( 27381216 )
2016
415
Genotypes of rubella virus and the epidemiology of rubella infections in the Democratic Republic of the Congo, 2004-2013. ( 27479298 )
2016
416
Corrigendum to "Evaluation of sensitivity of TaqMan RT-PCR for rubella virus detection in clinical specimens" [J. Clin. Virol. 80 (2016) 98-101]. ( 27523613 )
2016
417
Rubella Immune Status in Pregnant Women in a Northern Mexican City. ( 27540439 )
2016
418
Rubella immune status of neonates - a window towards seroprevalence among childbearing women. ( 27542838 )
2016
419
Comparing the rubella seronegativity in pregnant women who received one dose of rubella vaccine at different ages in Taiwan. ( 27544587 )
2016
420
Economic impact of switching rubella IgG methodologies to the prenatal public health program in Alberta. ( 27567094 )
2016
421
Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. ( 27613149 )
2016
422
Invasion Dynamics of Teratogenic Infections in Light of Rubella Control: Implications for Zika Virus. ( 27617170 )
2016
423
Zika Virus Is More Like Rubella Than Human Immunodeficiency Virus. ( 27617787 )
2016
424
Zika Virus Is More Like Rubella Than Human Immunodeficiency Virus-Reply. ( 27617894 )
2016
425
Genetic Characterization of Rubella Virus Strains Detected in Spain, 1998-2014. ( 27622271 )